Tag: omicron variant

COVID Infection Provides Immunity Equal to Vaccination: Study

Tina Marie (Ms. Cat)

COVID Infection Provides Immunity Equal to Vaccination: Study

Feb. 17, 2023 — The natural immunity provided by a COVID infection protects a person against severe illness on a par with two doses of mRNA vaccine, a new study says.

…

But protection against the BA.1 subvariant of Omicron was not as high – 36% at 10 months after infection, says the research team from the Institute for Health Metrics and Evaluation at the University of Washington.

The researchers examined 65 studies from 19 countries through Sept. 31, 2022. They did not study data about infection from Omicron XBB and its sub-lineages. People who had immunity from both infection and vaccination, known as hybrid immunity, were not studied.

MoA: China – Protest Instigators And Zero-Covid Policies

Tina Marie (Ms. Cat)
Telegram Screenshot. Translation by Yandex.

Within the last two days the New York Times produced four anti-China opinion pieces:

Are the Chinese Protests a Moment or a Movement?

The Communist Party Is Losing China’s People

Banana Peels for Xi Jinping

Xi Broke the Social Contract That Helped China Prosper

All four predict doom for China and president Xi’s leadership. In typical color-revolution fashion the sudden onslaught of these pieces follows recent reports of minor protests in some Chinese cities related to zero-Covid measures.

China – Protest Instigators And Zero-Covid Policies

Beijing to Let Some Low-Risk Patients Home Quarantine as Covid Soars + Some Notes

Tina Marie (Ms. Cat)1 Comment

Bloomberg: Beijing to Let Some Low-Risk Patients Home Quarantine as Covid Soars

Global Times: Flexible measures implemented across China to ensure people’s livelihoods amid cold front

China actually started relaxing it’s Zero-COVID polices on November 11th. The mNRA vaccine hasn’t been approved, yet. The West is pushing for China to use mNRA vaccines.

Related:

05-09-2022: Dropping zero-COVID policy in China without safeguards risks 1.5m lives – study

China’s refusal to use Western COVID-19 vaccines is making its protest problems even worse

Read More »

Scientists Find a New Coronavirus in Bats That Is Resistant to Current Vaccines

Tina Marie (Ms. Cat)

Scientists Find a New Coronavirus in Bats That Is Resistant to Current Vaccines

The findings come as the World Health Organization’s (WHO) ACT—Accelerator’s Council Tracking and Accelerating Progress—working group report that continued response to the COVID-19 pandemic, in the form of testing, vaccinations, and treatments, is stalling. With lower global immunity to the current SARS-CoV-2 virus, combating any new pathogens, including new coronaviruses like Khosta-2, would become more difficult. According to the latest data collected by the WHO, a quarter of people around the world still have not received a primary series of COVID-19 vaccination.

They just won’t give up! It’s over!

New COVID Booster Approved From Final Study of Mice, Not Humans, But Using Only Animal Data Is a Needless Gamble

Tina Marie (Ms. Cat)

VERIFY: New COVID booster approved from final study of mice, not humans

According to documents on the CDC website, human tests of Moderna’s version of the new booster are still “ongoing.” Right now, there is only final evidence from “8-10 mice” per group.”

The FDA’s website shows for Pfizer the agency also relayed on the final study evidence from “8 mice.” But human trials are also ongoing. So far, the new boosters “showed a similar local reaction and systemic event profile.” That means side effects appear to be about the same including “mild to moderate injection site pain, fatigue, and muscle pain.”

…

“To advance the Omicron BA.4/BA.5 bivalent vaccine as rapidly as possible, regulators, including the FDA, WHO and EMA, have advised that our submissions be based on safety and immunogenicity data generated in adults with an Omicron BA.1 bivalent vaccine and supported by BA.4/BA.5 bivalent pre-clinical data and BA.4/BA.5 bivalent quality and manufacturing data. These packages follow a similar model to that provided to public health officials who evaluate seasonal flu vaccines each year. Moving forward, this approach may help address the pressing need for vaccines that provide a high level of protection against current and emerging variants of concern so that we can remain vigilant against this evolving virus. The FDA has authorized our Omicron BA.4/BA.5 bivalent vaccine based on clinical data generated in adults with an Omicron BA.1 bivalent vaccine, pre-clinical data with a BA.4/BA.5 bivalent vaccine and BA.4/BA.5 bivalent quality and manufacturing data. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5- bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5 bivalent vaccine in individuals 12 years of age and older is ongoing. Data will be shared with regulators when available. We are facing a virus with an exceptionally high mutation rate, which the nimble mRNA platform is well situated to address. Only the mRNA sequence requires updating to match emerging strains, and utilizing a bivalent vaccine aims to provide broader coverage against known and future COVID-19 variants of concern.”

Related:

Read More »

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

Tina Marie (Ms. Cat)

Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults

The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.

…

Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.

…

Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.

…

The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.

…

Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.

Bill Gates and the Secret Push to Save Biden’s Climate Bill

Tina Marie (Ms. Cat)

Bill Gates and the Secret Push to Save Biden’s Climate Bill

Gates started wooing Manchin and other senators who might prove pivotal for clean-energy policy in 2019 over a meal in Washington DC. “My dialogue with Joe has been going on for quite a while,” Gates said. “Almost everyone on the energy committee” — of which Manchin was then the senior-most Democrat — “came over and spent a few hours with me over dinner.”

…

Also at Manchin’s insistence, automakers also will see new strings attached to electric vehicle tax incentives so they will have to be made in North America and, by 2024, can’t use batteries sourced from China. Labor leaders bemoaned that the final package doesn’t contain much support for workers who lose their jobs in the green transition.

…

There’s been such whiplash from 2016 when, as Gates puts it, green spending from the US government “had dropped to near zero.” Six years later, American climate finance has been “reinvigorated,” and Gates now sees innovation “going way faster than I expected. That’s why I’m optimistic that we will solve this thing.”

The working class is going to be thrown under the bus, but at least Bill Gates is happy. 🤷🏼‍♀️